Strengthening acute flaccid paralysis surveillance post Ebola virus disease outbreak 2015 - 2017: the Liberia experience.


Journal

The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926

Informations de publication

Date de publication:
2019
Historique:
received: 16 08 2018
accepted: 15 04 2019
entrez: 13 8 2019
pubmed: 14 8 2019
medline: 7 9 2019
Statut: epublish

Résumé

Liberia remains at high risk of poliovirus outbreaks due to importation. The country maintained certification level acute flaccid paralysis (AFP) surveillance indicators each year until 2014 due to Ebola outbreak. During this time, there was a significant drop in non-polio AFP rate to (1.2/100,000 population under 15 years) in 2015 from 2.9/100, 000 population in 2013, due to a variety of reasons including suspension on shipment of acute flaccid paralysis stool specimen to the polio regional lab in Abidjan, refocusing of surveillance officers attention solely on Ebola virus disease (EVD) surveillance, inactivation of national polio expert committee (NPEC) and National Certification Committee (NCC). The Ministry of Health (MOH) supported by partners worked to restore AFP surveillance post EVD outbreak and ensure that Liberia maintains its polio free certification. We conducted a desk review to summarize key activities conducted to restore acute flaccid paralysis (AFP) surveillance based on World Health Organization (WHO) AFP surveillance guidelines for Africa region. We also reviewed AFP surveillance indicators and introduction of new technologies. Data sources were from program reports, scientific and gray literature, AFP database, auto visual AFP detection and reporting (AVADAR) and ONA Servers. Data analysis was done using Microsoft excel and access spread sheets, ONA software and Geographic Information System (Arc GIS). AFP surveillance indicators improved with a rebound of non-polio AFP rate (NPAFP) rate from 1.2/100, 000 population under 15 years in 2015 to 4.3 in 2017. The stool adequacy rate at the national level also improved from 79% in 2016 to 82% in 2017, meeting the global target. The percentage of counties meeting the two critical AFP surveillance indicators NPAFP rate and stool adequacy improved from 47% in 2016 to 67% in 2017.The Last polio case reported in Liberia was in late 2010. There was significant improvement in the key AFP surveillance indicators such as NPAFP rate and stool adequacy with a 3.5 fold increase in NPAFP from 2014 to 2017. By 2017, the stool adequacy rate was up to target levels compared to 2016, which was below target level of 80%. The number of counties meeting target for the two critical AFP surveillance indicators also increased by 20% points between 2016 and 2017. Similarly there was approximately two-fold increase in the oral polio vaccines (OPV) coverage for the reported AFP cases between 2015 and 2017. Strategies employed to address gaps in AFP surveillance included enhanced active case search for AFP, re-instatement of laboratory testing, supportive supervision in addition to facilitating enhanced community engagement in surveillance activities. New technologies such as AVADAR Pilot, electronic integrated supportive supervision (ISS) and electronic surveillance (eSurv) tools were introduced to improve real time AFP case reporting. However, there remain residual gaps in AFP surveillance in the country especially at the sub-national level. Similarly, the newly introduced technologies will require continued funding and capacity building for MOH staff to ensure sustainability of the initiatives.

Identifiants

pubmed: 31402963
doi: 10.11604/pamj.supp.2019.33.2.16848
pii: PAMJ-SUPP-33-2-02
pmc: PMC6675926
doi:

Substances chimiques

Poliovirus Vaccine, Oral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Int J Health Geogr. 2002 Dec 9;1(1):4
pubmed: 12537589
Bull World Health Organ. 2005 Apr;83(4):268-73
pubmed: 15868017
Am J Epidemiol. 2010 Dec 1;172(11):1213-29
pubmed: 20978089
J Infect Dis. 2011 Apr 1;203(7):898-909
pubmed: 21402542
Pan Afr Med J. 2011;9:32
pubmed: 22145065
Pan Afr Med J. 2013 Mar 05;14:86
pubmed: 23646222
J Infect Dis. 2014 Nov 1;210 Suppl 1:S40-9
pubmed: 25316862
J Infect Dis. 2014 Nov 1;210 Suppl 1:S50-61
pubmed: 25316874
N Engl J Med. 2014 Oct 16;371(16):1476-9
pubmed: 25317869
Acta Inform Med. 2014 Dec;22(6):402-5
pubmed: 25684850
Vaccine. 2016 Oct 10;34(43):5187-5192
pubmed: 27396492
Vaccine. 2016 Oct 10;34(43):5144-5149
pubmed: 27431421
J Infect Dis. 2017 Jul 1;216(suppl_1):S293-S298
pubmed: 28838175
J Infect Dis. 2017 Jul 1;216(suppl_1):S343-S350
pubmed: 28838184
Pan Afr Med J. 2017 Jun 09;27(Suppl 2):10
pubmed: 28890751
PLoS Curr. 2017 Nov 9;9:
pubmed: 29188127

Auteurs

Adolphus Clarke (A)

Ministry of Health Monrovia, Monrovia, Liberia.

Nicholas Blidi (N)

Ministry of Health Monrovia, Monrovia, Liberia.

Bernice Dahn (B)

Ministry of Health Monrovia, Monrovia, Liberia.

Chukwuemeka Agbo (C)

World Health Organization, Country Office, Monrovia, Liberia.

Roland Tuopileyi (R)

World Health Organization, Country Office, Monrovia, Liberia.

Monday Julius Rude (MJ)

World Health Organization, Country Office, Monrovia, Liberia.

George Sie Williams (GS)

World Health Organization, Country Office, Monrovia, Liberia.

Mohammed Seid (M)

World Health Organization, Country Office, Monrovia, Liberia.

Alex Gasasira (A)

World Health Organization, Country Office, Monrovia, Liberia.

Zakari Wambai (Z)

National Public Health Institute of Liberia, Monrovia, Liberia.

Laura Skrip (L)

National Public Health Institute of Liberia, Monrovia, Liberia.

Thomas Nagbe (T)

National Public Health Institute of Liberia, Monrovia, Liberia.

Tolbert Nyenswah (T)

National Public Health Institute of Liberia, Monrovia, Liberia.

Joseph Okeibunor Chukwudi (JO)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ticha Johnson (T)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ambrose Talisuna (A)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ali Ahmed Yahaya (AA)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Soatiana Rajatonirina (S)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ibrahima Socé Fall (IS)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH